Scarica l'app Stockscreener
0.7872
1.59%
0.0144
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.7728
Aprire:
$0.77
Volume 24 ore:
335.61K
Relative Volume:
0.29
Capitalizzazione di mercato:
$101.93M
Reddito:
-
Utile/perdita netta:
$-26.91M
Rapporto P/E:
-3.5782
EPS:
-0.22
Flusso di cassa netto:
$-19.57M
1 W Prestazione:
-0.34%
1M Prestazione:
-16.35%
6M Prestazione:
-3.67%
1 anno Prestazione:
-39.61%
Intervallo 1D:
$0.7622
$0.7972
Intervallo di 1 settimana:
$0.755
$0.807
Portata 52W:
$0.5526
$1.66
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Nome
Atossa Therapeutics Inc
Settore
Industria
Telefono
206.588.0256
Indirizzo
10202 5TH AVENUE NE, SEATTLE, WA
Confronta ATOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.7891 | 98.60M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.59 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.96 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.31 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.35 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
301.83 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-01-26 | Iniziato | Maxim Group | Buy |
Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie
Should you wait for a breakout in Atossa Therapeutics Inc.July 2025 Reactions & Capital Efficient Trading Techniques - Newser
Technical analysis overview for Atossa Therapeutics Inc. stockJuly 2025 Pullbacks & Low Drawdown Investment Strategies - Newser
Ranking Atossa Therapeutics Inc. among high performing stocks via toolsTrade Analysis Summary & AI Optimized Trade Strategies - Newser
Atossa Therapeutics Advances Breast Cancer Treatments - TipRanks
What does recent volatility data suggest for Atossa Therapeutics Inc. [July 2025 News Drivers]Weekly Breakout Opportunity Watchlist - Newser
Can momentum traders help lift Atossa Therapeutics Inc.Short-Term Price Breakout Signal Analysis - Newser
Atossa Therapeutics Inc. stock momentum explainedDaily Breakout List with Smart Filters - Newser
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Applying sector rotation models to Atossa Therapeutics Inc. [July 2025 Rallies]Risk Controlled Stock Pick Alerts - Newser
Leading vs lagging indicators on Atossa Therapeutics Inc. performanceHigh Probability Trade Outcome Prediction - Newser
Why Atossa Therapeutics Inc. stock attracts strong analyst attentionPortfolio Review Summary with Five-Year Outlook - Newser
Short Term Charts Align With Long Term Uptrend in Atossa Therapeutics Inc.Growth Based Stock Signal Screener Updated - 선데이타임즈
Atossa Therapeutics' Q2 2025 Earnings: Navigating Financial Losses and the Promise of (Z)-endoxifen in Metastatic Breast Cancer - AInvest
Atossa Therapeutics Q2 2025 Financial Results and Corporate Update - TradingView
FDA Fast-Tracks Atossa's Breast Cancer Drug as Clinical Trial Shows 77% Tumor Reduction - Stock Titan
Risk vs reward if holding onto Atossa Therapeutics Inc.Free Pattern Alert With ROI Driven Strategy - Newser
What the charts say about Atossa Therapeutics Inc. todayAI Model Forecasting Reversal and Breakout Zones - Newser
Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update - Ariva
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Pensacola News Journal
How moving averages guide Atossa Therapeutics Inc. tradingEquity Market Return Forecast Model Update - Newser
New Product Launches: Will They Boost Atossa Therapeutics Inc. Stock in 2025Free Sector Rotation Based Trading Opportunities - Newser
What makes Atossa Therapeutics Inc. stock price move sharplyFree Growth Based Stock Signal Screener - Newser
Is Atossa Therapeutics Inc. building a consolidation baseTrade Signal Summary & Consistent Profit Trade Alerts - Newser
What does recent volatility data suggest for Atossa Therapeutics Inc.Secure Trading Strategy Based on Technical Analysis - Newser
What recovery options are there for Atossa Therapeutics Inc.Predictable Return Strategy with AI Support - Newser
Atossa Therapeutics Inc. Uptrend in Early Stages Indicators Say YesReversal Alert Based on RSI Indicator Confirmed - beatles.ru
Published on: 2025-08-09 01:47:05 - Newser
Does Atossa Therapeutics Inc. show high probability of reboundFree Consistent Gain Investment Strategies - Newser
Atossa Genetics (ATOS) Expected to Announce Earnings on Monday - Defense World
Will Atossa Therapeutics Inc. benefit from macro trendsLow Drawdown Stock Screener with Analysis - Newser
Atossa Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Published on: 2025-08-05 01:42:52 - Newser
Published on: 2025-08-04 22:41:33 - Newser
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4 - 富途牛牛
Is Atossa Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis Inside - Newser
Should I hold or sell Atossa Therapeutics Inc. stock in 2025Build a diversified portfolio for risk mitigation - Jammu Links News
What analysts say about Atossa Therapeutics Inc. stockAchieve breakthrough investment performance - Jammu Links News
When is Atossa Therapeutics Inc. stock expected to show significant growthExceptional gains - Jammu Links News
What is the risk reward ratio of investing in Atossa Therapeutics Inc. stockTrack top-performing stocks in real-time - Jammu Links News
How volatile is Atossa Therapeutics Inc. stock compared to the marketHigh-yield portfolio picks - Jammu Links News
Atossa Therapeutics Inc Azioni (ATOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atossa Therapeutics Inc Azioni (ATOS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):